Abstract
Inflammatory markers are increased in end stage renal disease (ESRD) especially diabetic patients and are positively correlated to cardiovascular mortality. Coenzyme Q10 (CO-Q10) a substance with antioxidant properties, may be effective in reducing cardiovascular complications in hemodialysis patients. The aim of this study was to investigate effects of CO-Q10 supplementation on plasma C-reactive protein, homocysteine and albumin in hemodialysis patients. Forty diabetic ESRD patients with at least 6 months on hemodialysis were evaluated in a double blind randomized clinical trial. The patients were randomly assigned into one of the two groups receiving CO-Q10 100 mg daily and placebo. In all patients serum levels of homocysteine, albumin and CRP were measured before and after 6 months. Mean age of the patients was 60.3 ± 9.1 years and 57.5 % were male. There was no statistically difference between two groups at baseline. Furthermore, no significant difference was observed in serum albumin (P=0.843), CRP (P=0.214) and homocysteine (P=0.21) at the end of intervention between groups. This study showed that in patients with ESRD, using CO-Q10 supplementation has minimal beneficial effects on serum albumin, CRP and homocysteine levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
